Phase I Trial of Carfilzomib (PR-171) in Combination With Vorinostat (SAHA) in Patients With Relapsed/Refractory B-Cell Lymphomas.

Trial Profile

Phase I Trial of Carfilzomib (PR-171) in Combination With Vorinostat (SAHA) in Patients With Relapsed/Refractory B-Cell Lymphomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Carfilzomib (Primary) ; Vorinostat (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Nov 2013 Planned end date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top